Skip to main content
Top
Published in: Current Diabetes Reports 5/2011

01-10-2011

Recurrence of Autoimmunity Following Pancreas Transplantation

Authors: George W. Burke III, Francesco Vendrame, Antonello Pileggi, Gaetano Ciancio, Helena Reijonen, Alberto Pugliese

Published in: Current Diabetes Reports | Issue 5/2011

Login to get access

Abstract

Pancreas transplantation is a therapeutic option for patients with type 1 diabetes. Advances in immunosuppression have reduced immunologic failures, and these are usually categorized as chronic rejection. Yet studies in our cohort of pancreas transplant recipients identified several patients in whom chronic islet autoimmunity led to recurrent diabetes, despite immunosuppression that prevented rejection. Recurrent diabetes in our cohort is as frequent as chronic rejection, and thus is a significant cause of immunologic graft failure. Our studies demonstrated islet autoimmunity by the presence of autoantibodies and autoreactive T cells, which mediated ß-cell destruction in a transplantation model. Biopsy of the transplanted pancreas revealed variable degrees of ß-cell loss, with or without insulitis, in the absence of pancreas and kidney transplant rejection. Additional research is needed to better understand recurrent disease and to identify new treatment regimens that can suppress autoimmunity, as in our experience this is not effectively inhibited by conventional immunosuppression.
Literature
1.
2.
go back to reference Sageshima J, Ciancio G, Gaynor JJ, et al. Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. Clin Transplant. 2011;25(2):E132–5.PubMedCrossRef Sageshima J, Ciancio G, Gaynor JJ, et al. Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. Clin Transplant. 2011;25(2):E132–5.PubMedCrossRef
3.
go back to reference Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2010;10(2):398–406.PubMedCrossRef Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2010;10(2):398–406.PubMedCrossRef
4.
go back to reference Dean PG, Kudva YC, Larson TS, Kremers WK, Stegall MD. Posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2008;8(1):175–82.PubMed Dean PG, Kudva YC, Larson TS, Kremers WK, Stegall MD. Posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2008;8(1):175–82.PubMed
5.
go back to reference Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80–7.PubMed Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80–7.PubMed
6.
go back to reference Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53(2):132–44.PubMed Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53(2):132–44.PubMed
7.
go back to reference Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38(S1):85–7.PubMed Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38(S1):85–7.PubMed
8.
go back to reference Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med. 1996;335(12):860–3.PubMedCrossRef Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med. 1996;335(12):860–3.PubMedCrossRef
9.
go back to reference Santamaria P, Nakhleh RE, Sutherland DE, Barbosa JJ. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes. 1992;41(1):53–61.PubMedCrossRef Santamaria P, Nakhleh RE, Sutherland DE, Barbosa JJ. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes. 1992;41(1):53–61.PubMedCrossRef
10.
go back to reference • Vendrame F, Pileggi A, Laughlin E et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59(4):947–57. This article is the original source for much of the data reviewed in this article.PubMedCrossRef • Vendrame F, Pileggi A, Laughlin E et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59(4):947–57. This article is the original source for much of the data reviewed in this article.PubMedCrossRef
11.
go back to reference • Ishida-Oku M, Iwase M, Sugitani A et al. A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor. Diabetologia 2010; 53(2):341–5. This article identified another case of recurrent diabetes in an immunosuppressed patient.PubMedCrossRef • Ishida-Oku M, Iwase M, Sugitani A et al. A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor. Diabetologia 2010; 53(2):341–5. This article identified another case of recurrent diabetes in an immunosuppressed patient.PubMedCrossRef
12.
go back to reference Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128(1):151–70.PubMed Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128(1):151–70.PubMed
13.
go back to reference Bosi E, Bottazzo GF, Secchi A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes. 1989;38(S1):82–4.PubMed Bosi E, Bottazzo GF, Secchi A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes. 1989;38(S1):82–4.PubMed
14.
go back to reference Esmatjes E, Rodriguez-Villar C, Ricart MJ, et al. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation. 1998;66(1):128–31.PubMedCrossRef Esmatjes E, Rodriguez-Villar C, Ricart MJ, et al. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation. 1998;66(1):128–31.PubMedCrossRef
15.
go back to reference Petruzzo P, Andreelli F, McGregor B, et al. Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab. 2000;26(3):215–8.PubMed Petruzzo P, Andreelli F, McGregor B, et al. Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab. 2000;26(3):215–8.PubMed
16.
go back to reference Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation. 2000;69(1):99–103.PubMedCrossRef Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation. 2000;69(1):99–103.PubMedCrossRef
17.
go back to reference Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49(2):218–24.PubMedCrossRef Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49(2):218–24.PubMedCrossRef
18.
go back to reference Hilbrands R, Huurman VA, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58(10):2267–76.PubMedCrossRef Hilbrands R, Huurman VA, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58(10):2267–76.PubMedCrossRef
19.
go back to reference Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008;3(6):e2435.PubMedCrossRef Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008;3(6):e2435.PubMedCrossRef
20.
go back to reference Diamantopoulos S, Allende G, Martin-Pagola A, et al. Recurrence of type 1 diabetes (T1DR) after simultaneous pancreas-kidney (SPK) transplantation is associated with islet cell autoantibody conversion. Acta Diabetol. 2007;44(S1):S13. Diamantopoulos S, Allende G, Martin-Pagola A, et al. Recurrence of type 1 diabetes (T1DR) after simultaneous pancreas-kidney (SPK) transplantation is associated with islet cell autoantibody conversion. Acta Diabetol. 2007;44(S1):S13.
21.
go back to reference Sundkvist G, Tyden G, Karlsson FA, Bolinder J. Islet autoimmunity before and after pancreas transplantation in patients with Type I diabetes mellitus. Diabetologia. 1998;41(12):1532–3.PubMedCrossRef Sundkvist G, Tyden G, Karlsson FA, Bolinder J. Islet autoimmunity before and after pancreas transplantation in patients with Type I diabetes mellitus. Diabetologia. 1998;41(12):1532–3.PubMedCrossRef
22.
go back to reference Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128(1):23–30.PubMedCrossRef Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128(1):23–30.PubMedCrossRef
23.
go back to reference Reijonen H, Geubtner K, Allende G, et al. Identification of islet-autoantigen specific CD4+ T-cells in the pancreatic lymph nodes and pancreas of a pancreas-kidney transplant patient with recurrence of autoimmunity. Diabetes. 2006;55(S1):88A. Reijonen H, Geubtner K, Allende G, et al. Identification of islet-autoantigen specific CD4+ T-cells in the pancreatic lymph nodes and pancreas of a pancreas-kidney transplant patient with recurrence of autoimmunity. Diabetes. 2006;55(S1):88A.
24.
go back to reference Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261–70.PubMedCrossRef Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261–70.PubMedCrossRef
25.
go back to reference Smukler SR, Arntfield ME, Razavi R, et al. The adult mouse and human pancreas contain rare multipotent stem cells that express insulin. Cell Stem Cell. 2011;8(3):281–93.PubMedCrossRef Smukler SR, Arntfield ME, Razavi R, et al. The adult mouse and human pancreas contain rare multipotent stem cells that express insulin. Cell Stem Cell. 2011;8(3):281–93.PubMedCrossRef
26.
go back to reference Bonner-Weir S, Li WC, Ouziel-Yahalom L, et al. Beta-cell growth and regeneration: replication is only part of the story. Diabetes. 2010;59(10):2340–8.PubMedCrossRef Bonner-Weir S, Li WC, Ouziel-Yahalom L, et al. Beta-cell growth and regeneration: replication is only part of the story. Diabetes. 2010;59(10):2340–8.PubMedCrossRef
27.
go back to reference Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic beta-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53.PubMedCrossRef Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic beta-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53.PubMedCrossRef
28.
go back to reference Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57(6):1584–94.PubMedCrossRef Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57(6):1584–94.PubMedCrossRef
29.
go back to reference Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab. 2007;3(11):758–68.PubMedCrossRef Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab. 2007;3(11):758–68.PubMedCrossRef
30.
go back to reference Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48(11):2221–8.PubMedCrossRef Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48(11):2221–8.PubMedCrossRef
31.
go back to reference Melmed RN, Benitez CJ, Holt SJ. Intermediate cells of the pancreas. I. Ultrastructural characterization. J Cell Sci. 1972;11(2):449–75.PubMed Melmed RN, Benitez CJ, Holt SJ. Intermediate cells of the pancreas. I. Ultrastructural characterization. J Cell Sci. 1972;11(2):449–75.PubMed
32.
go back to reference Yatoh S, Dodge R, Akashi T, et al. Differentiation of affinity-purified human pancreatic duct cells to beta-cells. Diabetes. 2007;56(7):1802–9.PubMedCrossRef Yatoh S, Dodge R, Akashi T, et al. Differentiation of affinity-purified human pancreatic duct cells to beta-cells. Diabetes. 2007;56(7):1802–9.PubMedCrossRef
33.
go back to reference Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC. Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia. 2005;49:83–9.PubMedCrossRef Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC. Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia. 2005;49:83–9.PubMedCrossRef
34.
go back to reference Juhl K, Bonner-Weir S, Sharma A. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant. 2010;15(1):79–85.PubMedCrossRef Juhl K, Bonner-Weir S, Sharma A. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant. 2010;15(1):79–85.PubMedCrossRef
35.
go back to reference Martin-Pagola A, Sisino G, Allende G, et al. Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia. 2008;51(10):1803–13.PubMedCrossRef Martin-Pagola A, Sisino G, Allende G, et al. Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia. 2008;51(10):1803–13.PubMedCrossRef
36.
go back to reference Jonsson J, Ahlgren U, Edlund T, Edlund H. IPF1, a homeodomain protein with a dual function in pancreas development. Int J Dev Biol. 1995;39(5):789–98.PubMed Jonsson J, Ahlgren U, Edlund T, Edlund H. IPF1, a homeodomain protein with a dual function in pancreas development. Int J Dev Biol. 1995;39(5):789–98.PubMed
37.
go back to reference Tanaka S, Kobayashi T, Nakanishi K, et al. Evidence of primary beta-cell destruction by T-cells and beta-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care. 2001;24(9):1661–7.PubMedCrossRef Tanaka S, Kobayashi T, Nakanishi K, et al. Evidence of primary beta-cell destruction by T-cells and beta-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care. 2001;24(9):1661–7.PubMedCrossRef
38.
go back to reference Bottino R, Criscimanna A, Casu A, et al. Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation. Diabetes. 2009;58(2):442–7.PubMedCrossRef Bottino R, Criscimanna A, Casu A, et al. Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation. Diabetes. 2009;58(2):442–7.PubMedCrossRef
39.
go back to reference Wang GS, Rosenberg L, Scott FW. Tubular complexes as a source for islet neogenesis in the pancreas of diabetes-prone BB rats. Lab Invest. 2005;85(5):675–88.PubMedCrossRef Wang GS, Rosenberg L, Scott FW. Tubular complexes as a source for islet neogenesis in the pancreas of diabetes-prone BB rats. Lab Invest. 2005;85(5):675–88.PubMedCrossRef
40.
go back to reference Kauri LM, Wang GS, Patrick C, et al. Increased islet neogenesis without increased islet mass precedes autoimmune attack in diabetes-prone rats. Lab Invest. 2007;87(12):1240–51.PubMedCrossRef Kauri LM, Wang GS, Patrick C, et al. Increased islet neogenesis without increased islet mass precedes autoimmune attack in diabetes-prone rats. Lab Invest. 2007;87(12):1240–51.PubMedCrossRef
41.
go back to reference Xu X, D’Hoker J, Stange G, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008;132(2):197–207.PubMedCrossRef Xu X, D’Hoker J, Stange G, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008;132(2):197–207.PubMedCrossRef
42.
go back to reference Xia B, Zhan XR, Yi R, Yang B. Can pancreatic duct-derived progenitors be a source of islet regeneration? Biochemistry Biophysics Res Commun. 2009;383(4):383–5.CrossRef Xia B, Zhan XR, Yi R, Yang B. Can pancreatic duct-derived progenitors be a source of islet regeneration? Biochemistry Biophysics Res Commun. 2009;383(4):383–5.CrossRef
43.
go back to reference Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol. 2008;127(3):359–65.PubMedCrossRef Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol. 2008;127(3):359–65.PubMedCrossRef
44.
go back to reference Unger WW, Pinkse GG, der Mulder-van KS, et al. Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men. Ann N Y Acad Sci. 2007;1103:192–5.PubMedCrossRef Unger WW, Pinkse GG, der Mulder-van KS, et al. Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men. Ann N Y Acad Sci. 2007;1103:192–5.PubMedCrossRef
45.
go back to reference King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117(2):265–77.PubMedCrossRef King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117(2):265–77.PubMedCrossRef
46.
go back to reference Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest. 2002;109(7):895–903.PubMed Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest. 2002;109(7):895–903.PubMed
47.
go back to reference Monti P, Scirpoli M, Rigamonti A, et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol. 2007;179(9):5785–92.PubMed Monti P, Scirpoli M, Rigamonti A, et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol. 2007;179(9):5785–92.PubMed
48.
go back to reference Monti P, Heninger AK, Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep. 2009;9(2):113–8.PubMedCrossRef Monti P, Heninger AK, Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep. 2009;9(2):113–8.PubMedCrossRef
49.
go back to reference • Monti P, Scirpoli M, Maffi P et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 2008;118(5):1806–14. This article provides evidence for a role of memory cells in patients with islet cell transplants.PubMed • Monti P, Scirpoli M, Maffi P et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 2008;118(5):1806–14. This article provides evidence for a role of memory cells in patients with islet cell transplants.PubMed
50.
go back to reference Matthews JB, Staeva TP, Bernstein PL, Peakman M. von HM. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol. 2010;160(2):176–84.PubMedCrossRef Matthews JB, Staeva TP, Bernstein PL, Peakman M. von HM. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol. 2010;160(2):176–84.PubMedCrossRef
Metadata
Title
Recurrence of Autoimmunity Following Pancreas Transplantation
Authors
George W. Burke III
Francesco Vendrame
Antonello Pileggi
Gaetano Ciancio
Helena Reijonen
Alberto Pugliese
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 5/2011
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-011-0206-y

Other articles of this Issue 5/2011

Current Diabetes Reports 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine